Impact of microparticle-based drug delivery systems on patient adherence in diabetes management: A literature-based perspective
DOI:
https://doi.org/10.29070/n4ra1120Keywords:
Microparticle drug delivery, Patient adherence, PLGA, Metformin, Controlled releaseAbstract
Diabetes mellitus represents a major chronic health condition requiring sustained pharmacological intervention, where patient adherence plays a critical role in determining therapeutic success. This study examines the impact of microparticle-based drug delivery systems on patient adherence in diabetes management, with particular emphasis on Metformin formulations using PLGA (Poly(lactic-co-glycolic acid)). The prime aim of the study is to critically evaluate how controlled-release microparticle systems influence adherence by reducing dosing frequency, improving tolerability, and enhancing overall patient acceptance.
The research adopts a qualitative, literature-based methodology relying exclusively on secondary data sources, including peer-reviewed open-access journal articles, clinical reports, and pharmaceutical studies. A thematic and comparative synthesis is conducted to analyze adherence patterns, pharmacokinetic behavior, formulation characteristics, and patient-reported outcomes associated with microparticle-based systems.
The findings indicate that sustained-release microparticle formulations significantly improve patient adherence by stabilizing plasma drug levels, minimizing gastrointestinal side effects, and simplifying dosing regimens. PLGA-based systems demonstrate high formulation stability, biocompatibility, and consistent drug release, contributing to improved therapeutic outcomes. The study also highlights that integrating pharmaceutical design with patient-centered considerations is essential for achieving long-term treatment compliance.
The study concludes that microparticle-based drug delivery systems offer a promising approach to overcoming adherence challenges in diabetes management. However, further clinical validation and integration with patient-focused healthcare strategies are necessary to maximize their real-world applicability.
Downloads
References
1. Brown, M. T., & Bussell, J. K. (2011). Medication adherence: WHO cares? Mayo Clinic Proceedings, 86(4), 304–314.
2. Claxton, A. J., Cramer, J., & Pierce, C. (2001). A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics, 23(8), 1296–1310.
3. Costa, E., Giardini, A., Savin, M., Menditto, E., Lehane, E., Laosa, O., Pecorelli, S., Monaco, A., & Marengoni, A. (2019). Interventional tools to improve medication adherence: Review of literature. Patient Preference and Adherence, 13, 1563–1581.
4. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 161(2), 505–522.
5. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 161(2), 505–522.
6. Davis, E. M., Packard, K. A., & Hilleman, D. E. (2021). Pharmacologic management of type 2 diabetes mellitus: Available therapies. American Journal of Health-System Pharmacy, 77(5), 319–330.
7. Deshpande, P. R., Rajan, S., Sudeepthi, B. L., & Nazir, C. P. (2018). Patient-reported outcomes: A new era in clinical research. Perspectives in Clinical Research, 2(4), 137–144.
8. Hughes, D. A. (2007). Medication non-adherence in patients with chronic disease: Issues in healthcare policy. Patient Preference and Adherence, 1, 315–321.
9. Jimmy, B., & Jose, J. (2011). Patient medication adherence: Measures in daily practice. Oman Medical Journal, 26(3), 155–159.
10. Kardas, P., Lewek, P., & Matyjaszczyk, M. (2013). Determinants of patient adherence: A review of systematic reviews. Frontiers in Pharmacology, 4, 91.
11. Krass, I., Schieback, P., & Dhippayom, T. (2015). Adherence to diabetes medication: A systematic review. Diabetic Medicine, 32(6), 725–737.
12. Kumari, A., Yadav, S. K., & Yadav, S. C. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and Surfaces B: Biointerfaces, 75(1), 1–18.
13. Lee, J. H., Yeo, Y., & Kim, J. S. (2015). Advanced drug delivery systems for diabetes management. Journal of Controlled Release, 219, 2–13.
14. Makadia, H. K., & Siegel, S. J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3(3), 1377–1397.
15. Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016). Diabetes medications as monotherapy or metformin-based combination therapy. Annals of Internal Medicine, 164(11), 740–751.
16. McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016). Metformin and the gastrointestinal tract. Diabetologia, 59(3), 426–435.
17. Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of Medicine, 353(5), 487–497.
18. Peppas, N. A., Bures, P., Leobandung, W., & Ichikawa, H. (2016). Hydrogels in pharmaceutical formulations. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 27–46.
19. Polonsky, W. H., & Henry, R. R. (2016). Poor medication adherence in type 2 diabetes: Recognizing the scope of the problem. Diabetes Care, 39(6), 905–909.
20. Shrivastava, S. R., Shrivastava, P. S., & Ramasamy, J. (2013). Role of self-care in management of diabetes mellitus. Journal of Diabetes & Metabolic Disorders, 12(1), 14.
21. Vllasaliu, D., Fowler, R., & Stolnik, S. (2014). PEGylated nanomedicines: Recent progress and remaining concerns. Expert Opinion on Drug Delivery, 11(1), 139–154.
